UK COVID-19 Vaccine Priority and Template Letters

Share on facebook
Share on twitter
Share on email

#MEAction UK recently wrote to the Joint Committee on Vaccination and Immunisation (JCVI). We requested clarity on where people with ME are placed in the priority groups laid out by the government for the COVID-19 vaccine in the UK.

We have now received a response. While the JCVI are not going to explicitly name ME within group six of the vaccine priority list, they do make it clear that this list is not exhaustive and clinical judgement should be applied:

The examples included are not exhaustive, and, the advice states that within these groups, the prescriber should apply clinical judgment to take into account the risk of COVID-19 exacerbating any underlying disease that a patient may have.

JCVI

Both the ME Association and Action for ME have developed template letters for people with ME to send to their GP requesting they are placed into group six.

We are hearing of varying levels of success, but consider this a worthwhile step to try. Find links to these template letters below:

ME Assocation Template Letter

Action for ME Template Letter

The JCVI have also stated they are open to receiving further evidence around the risk of increased morbidity related to COVID-19. This would include exacerbation of ME.

Identifying the remaining preventable morbidity burden from COVID19 is part of the considerations for phase 2 of the programme. If you have specific scientific evidence related to ME/CFS and the risk of increased morbidity from COVID-19, and can share these with JCVI, please let us know.

JCVI

#MEAction UK is working to provide further evidence to the JCVI on this matter. We will keep the community updated with our progress.

Read the full response from the JCVI:

Dear Charlie,

Thank you for your email. We also had an email from Dr Charles Shepherd raising similar concerns and I have included the response below.

Kind regards

Jonathan

For this first phase of the COVID-19 mass vaccination programme, JCVI has advised that, the first priorities should be the prevention of COVID-19 mortality and the protection of health and social care staff and systems.

Accordingly, the order of priority was based on estimates of the risk of dying from COVID-19. The priority order for Phase 1 reflects the estimated number of persons needed to vaccinate to save one life. It is estimated that the groups prioritised represent around 99% of preventable mortality from COVID-19.

Phase 1 is largely prioritised by age due to the very strong association of older age and increased mortality from COVID-19.  Persons aged >16 years with underlying health conditions that put them at higher risk of dying from COVID-19 are also included in Phase 1 of the programme. The Committee has not identified any robust data to indicate that, as a group, persons with ME/CFS are at higher risk of dying from COVID19 (see references below).

The Green Book immunisations against infectious disease (weblink included below) provides the details of the clinical risk groups in persons 16 years of age and over who should receive COVID-19 immunisation in Phase 1. The examples included are not exhaustive, and, the advice states that within these groups, the prescriber should apply clinical judgment to take into account the risk of COVID-19 exacerbating any underlying disease that a patient may have, as well as the risk of serious illness from COVID-19 itself.

The Committee has started the process for the development of advice  for the second phase of the immunisation programme. Identifying the remaining preventable morbidity burden from COVID19 is part of the considerations for phase 2 of the programme. If you have specific scientific evidence related to ME/CFS and the risk of increased morbidity from COVID-19, and can share these with JCVI, please let us know. The Committee will review these  as part of its considerations for phase 2 of the programme.

Yours sincerely

JCVI Secretariat

On behalf of

Professor Wei Shen Lim JCVI Chair COVID-19 immunisation

Consultant Respiratory Physician and Honorary Professor (Respiratory Medicine)

Nottingham University Hospitals

References

Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020 Aug;584(7821):430-436.

Clift AK, Coupland CAC, Keogh RH et al. Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. BMJ. 2020 Oct 20;371:m3731.

Green Book Immunisation against infectious disease COVID-19 chapter:

https://www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a

Share on facebook
Facebook
Share on twitter
Twitter
Share on whatsapp
WhatsApp
Share on email
Email

1 thought on “UK COVID-19 Vaccine Priority and Template Letters”

  1. It’s worth seeing if your CGG has an online booking system, in my area (Nottinghamshire) eligible people were encouraged to book prior to receiving their invite via letter or SMS I did this and got an appointment the next day. My SMS came through 2 days after I’d been vaccinated.
    I presume this must mean I can correctly in cohort 6 and when booked as I entered my NHS number it checked against a database for eligibility.

    https://nottsccg.nhs.uk/covid-19/covid-19-vaccination-booking-open-for-cohort-6/

Leave a Comment

Your email address will not be published. Required fields are marked *

Latest News

In Memory of Dr. Ronald G. Tompkins MD, ScD

Mourning the loss of Dr. Ron Tompkins

Today #MEAction joins the community in mourning the loss of Dr. Ronald G. Tompkins, MD, ScD, who passed away this week. Ron Tompkins was a clinician, clinical researcher, and friend and ally to people with ME. He was the Sumner M. Redstone Professor of Surgery at Harvard Medical School, Founding Director of the Center for

Read More »
National Institutes of Health campus buildings from above

NIH Long COVID research lacks clear plan to identify and track ME/CFS

MEAction has written to the National Institutes of Health (NIH) expressing our deep concern that the RECOVER Initiative research agenda lacks a clear plan for how to accurately identify or consistently track the onset of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) cases among patients with Long COVID. This is of particular importance because a sizable fraction

Read More »

The Last Two Years Changed the World…

What a year 2021 was! People with ME have always faced formidable challenges: every day combatting stigma, lack of understanding from clinicians, NIH’s and CDC’s low budgetary commitments, and a world of challenges navigating disability on top of symptoms.  It’s no exaggeration to say that 2020 and 2021 changed the world – and the world of chronic,

Read More »

Help keep our work going

We rely on donations from people like you to keep fighting for equality for people with ME.

Donate

Get actions alerts and news direct to your inbox

You can choose what you want to be kept up to date on.

Subscribe
Scroll to Top